Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 17/20 | 0.60 |
| ▸ | AR | P10275 | 4/20 | 0.60 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.52 |
| ▸ | CDK9 | P50750 | 1/20 | 0.48 |
| ▸ | BTK | Q06187 | 4/20 | 0.47 |
| ▸ | HPGDS | O60760 | 2/20 | 0.47 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.46 |
| ▸ | IRAK3 | Q9Y616 | 1/20 | 0.46 |
| ▸ | ITK | Q08881 | 1/20 | 0.45 |
| ▸ | PLK4 | O00444 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31055492 | 0.95 | CRBN (0.56) | CRBNARDDB1CDK9BTK | |
| SCHEMBL24671170 | 0.95 | CRBN (0.56) | CRBNARDDB1CDK9BTK | |
| SCHEMBL23754672 | 0.93 | CRBN (0.67) | CRBNARDDB1HPGDS | |
| SCHEMBL29927280 | 0.93 | CRBN (0.67) | CRBNARDDB1HPGDS | |
| SCHEMBL30693000 | 0.90 | CRBN (0.60) | CRBNARDDB1CDK9BTK | |
| SCHEMBL26928955 | 0.90 | CRBN (0.60) | CRBNARDDB1CDK9BTK | |
| SCHEMBL29132140 | 0.89 | CRBN (0.59) | CRBNARDDB1CDK9BTK | |
| SCHEMBL27176456 | 0.89 | CRBN (0.59) | CRBNARDDB1CDK9BTK | |
| SCHEMBL29927733 | 0.89 | CRBN (0.59) | CRBNARDDB1CDK9BTK | |
| SCHEMBL20231763 | 0.89 | CRBN (0.59) | CRBNARDDB1CDK9BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2024-01-25 | — | — | US | disclosed |
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2024-01-25 | — | — | US | disclosed |
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2024-01-25 | — | — | US | disclosed |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | CRBN 144/4885AR 2450/4885DDB1 438/4885 |
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | EGFR, ERBB2, CBL | CRBN 213/4885AR 1978/4885DDB1 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.